ACE Technology Guidances

ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 02 Sep 2019
Last Updated on 02 Sep 2019
A- A+
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
  • Clostridium botulinum toxin type A neurotoxin complex (Botox) 50 U and 100 U injection vials for treating children, aged 2 years or older, with focal spasticity of the upper or lower limbs (including dynamic equinus foot deformity) due to cerebral palsy, and who:
    • do not have significant joint contractures, i.e. the affected joint is not permanently fixed in position due to shortening of the target muscle; and
    • are concurrently receiving ongoing supportive therapy, e.g. physiotherapy or occupational therapy.
Botulinum toxin type A must be administered by a physician specialising in paediatric neurological disorders or paediatric rehabilitation with experience in administering botulinum toxin type A.

Subsidy status
Clostridium botulinum toxin type A neurotoxin complex (Botox) 50 U and 100 U injection vials are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication.

MAF does not apply to Botox 200 U injection vial, Dysport 300 U and 500 U injection vials, and Xeomin 50 U and 100 U injection vials.

 

Botulinum toxin A for focal spasticity of the upper or lower limbs in children with cerebral palsy (2 Sep 2019) PES Botulinum toxin A for treating focal spasticity of the upper or lower limbs in children with cerebral palsy (Published 2 Sep 2019)